Daily close, T-120 (1/15/25) through T+5. Run-up high $46.26 on 5/19/25, low $32.38 on 1/30/25 (T-120 to T-1). FDA decision 7/2/25. Historical price action, not a forecast.
Positioning before the decision
On Jun 18, 2025, 14 days before the decision date, at-the-money options priced a move of ±6.3% through Jul 18, 2025 (the first listed expiry after the decision; ATM implied volatility 27%). The stock closed +1.6% at the first close across the decision and +1.0% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Yes. The FDA approved the application for Zegfrovy (sunvozertinib) on July 2, 2025. The primary source is linked on this page.
What was Zegfrovy (sunvozertinib) under FDA review for?
The application covered NSCLC (EGFR exon 20 insertions). The FDA approved the application on July 2, 2025.
How did EXEL stock react to the FDA decision?
On the decision day EXEL moved +1.6%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.